Polatuzumab Vedotin: How can the POLARIX trial help us comprehend DLBCL? Connor Johnson MD By P. Connor Johnson, MD My name is Connor Johnson, and I am the medical oncologist at the Center for Lymphoma in the Massachusetts General Hospital Cancer Center. It is my privilege today to discuss the POLARIX trial, which potentially changes the standard of care for the treatment of diffuse large B-cell lymphoma, the most common lymphoma. The key takeaways from this talk are to review the current standard of care for diffuse large B-cell lymphoma and to recognize the significance of the POLARIX Phase III,…
Author: admin
Diabetes Cancer: Racial Disparities In Prevention An Epidemiological Perspective By Gaole Song By Gaole Song, DrPH From the City of Hope So far, for my research, I’m very interested in cancer prevention, cancer promotion, and also diabetes prevention from an epidemiological perspective. Cancer and diabetes are both serious public health issues in California State and Los Angeles County. Cancer is a leading cause of death in Los Angeles, and diabetes ranks sixth. These two diseases are very important, and both have obesity as an important cancer risk factors. Minority patients have a higher risk of developing cancer and diabetes…
Tafasitamab: Final Results of Five-Year Safety and Efficacy Study (Phase II L-MIND) Prof. Kalakonda By Professor Nagesh Kalakonda Thank you for this opportunity to talk about the L-MIND study. The study itself was initiated in 2016 and targeted relapsed refractory patients with diffuse large B-cell lymphoma. It was an open-label phase 2 study conducted in 10 countries and at 39 sites. The study was specifically targeted towards patients who were not eligible for an autologous stem cell transplantation, either with one previous line of therapy or multiple previous lines of therapy. This represents a population with an unmet need and…
Focal Adhesion Kinase: Can Adding Fibroblasts and C-X-C Chemokine Help With Suppression? Arsen Osipov MD By Arsen Osipov, MD In our study, we wanted to further investigate specific proteins in the tumor microenvironment of pancreatic cancer to understand their implications, particularly in a unique subset of patients. As we all know, pancreatic ductal adenocarcinoma is a very treatment-resistant tumor, and this is due to many mechanisms of resistance, mainly related to the tumor microenvironment, which is very dismal and immunosuppressive. One protein that our lab is interested in is focal adhesion kinase, a non-receptor protein tyrosine kinase that is abundantly…
Cancer Drug Research: Expanded Phase 1 Program to the Dallas Area Anthony Tolcher MD By Anthony Tolcher, MD One of the challenges that we all face right now is we are in this golden age of drug development where there’s so many new molecules being developed and we probably don’t have enough proficient and high quality phase 1 sites in the United States, Europe, and probably the world. So the issue here is that we are developing in our network multiple sites where we have professional phase 1 programs and clinics so that patients can access them through referral…
CD70: How Does ALLO-316 Eliminate or Destroy Malignancies in the TRAVERSE Trial? Samer Srour, MB ChB, MS By Samer Srour, MB ChB, MSs So the ALLO-316 is, it’s very novel agent to treat, kidney cancer and hopefully will expand to other cancers. It’s first of all, it’s take CAR T-cell Therapy antigen receptor, T-cell engineered treatment. The CAR T-cell therapy is groundbreaking right now and practice changing for those similar malignancies. We have FDA approved products for these malignancies. We are trying to pass on on this success for these solid tumors. And that’s where it comes to idea to…
Chimeric Antigen Receptor T-Cell Therapy: A Longitudinal Study Conner Johnson MD By Conner Johnson, MD Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapy treatment that has transformed the landscape for those with relapsed refractory hematologic malignancies. It is a treatment where we take white blood cells from a patient and create an autologous product that is an altered version of T-cells, which express an antigen receptor targeting the cancer. Then, those cells are rein-fused back into the patient. This treatment is approved in the relapse refractory setting for certain subtypes of non-Hodgkin’s lymphoma, multiple myeloma, and acute lymphoblastic leukemia.…
Test Test Test
Lisaftoclax (APG-2575): In CLL / SLL Treatment: Safety and Efficacy as Monotherapy or Combined with Acalabrutinib or Rituximab Matthew Davids By Matthew Davids, MD, MMSc So this is a brand new drug called Lisaftoclax, which is a BCL-2 inhibitor. BCL-2 inhibitors have also been developed, of course, like Venetoclax in the past, but this is a newer BCL-2 inhibitor that we’ve only seen very minimal data for in the past. There was a all-comer study of different hematologic malignancies small group of patients were presented last year. One of the things that was noted in that early phase one experience…
Trimodality: In addition to Trastuzumab for HER2+ Esophageal Adenocarcinoma: NRG Oncology RTOG 1010 Phase III Trial Lisa Kachnic MD By Lisa Kachnic, MD, FASTRO Good afternoon. Today I’m going to discuss the patient reported outcomes from NRG Oncology RTOG 1010 that I was delighted to talk about at our recent ASTRO Radiation Oncology meeting. And, NRG Oncology RTOG 1010 was a phase 3 randomized trial and it evaluated the addition of Trastuzumab or Herceptin the monoclonal antibody used to treat HER2+ receptor cancers, such as breast or metastatic stomach, and that was added to trimodality treatment of HER2 over expressing…
Acalabrutinib (AVO): A Promising New Triplet Treatment Option for High-Risk CLL Patients Phase 2 Study Results Matthew Davids By Matthew Davids, MD, MMSc This is a phase 2 investigator initiated clinical trial of a triplet regimen for the frontline treatment of CLL (chronic lymphocytic leukemia). And the 3 drugs are all FDA-approved already, including acalabrutinib. Venetoclax and Obinutuzumab, we call this the AVO (Acalabrutinib, Venetoclax, Obinutuzumab) study. And these drugs although approved in other combinations, are not approved together. So ours is one of the first studies to look at this triplet combination. We had actually previously published a paper…
Allogeneic Hematopoietic Cell Transplantation: How Can the ASAP Trial Help Relapsed or Refractory AML? Johannes Schetelig By Prof. Dr. med. Johannes Schetelig So I’m going to tell you about the ASAP trial. This was not a trial about a new compound. It was a trial about a strategy, how to bring patients to a transplantation. Patients who either failed chemotherapy due to relapse of AML or poor response of the first induction of chemotherapy and had an intermediate or high risk genetic risk profile have a clear indication for transplantation. The question was, as we addressed in this trial, how…
Treatment Patterns and Overall Survival (OS) Among Patients with Myelodysplastic Syndromes (MDS) Treated in the US Community Oncology Setting: A Real-World Retrospective Ontada Observational Study by: Ira Zackon, MD – USOncology Network So our study is a retrospective we call descriptive study, really looking at treatment patterns and improve patient outcomes with myelodysplastic syndromes or MDS. So this is leveraging the data within the electronic health record called Ontada, which is within USOncology. 1,400 physicians taking care of advance cancer care patients So again, reflective of the community based real world setting and it’s a large database with over 1,400…
Idecabtagene Vicleucel Shows Effectiveness and Safety in High-Risk Multiple Myeloma Patients Krina Patel MD By Krina Patel, MD, MSc So this trial is looking at ide-cel, or Idecabtagene Vicleucel, which is a CAR T-cell against BCMA, and it’s already been FDA-approved in a relapse-refractory setting for multiple myeloma patients. However, we have high risk patients in multiple myeloma that don’t really fit the same trajectory of disease control the way our standard risk patients do. And so those patients can’t wait to get these novel therapies in fifth line, which is where it’s approved. So this trial was actually looking…
Odronextamab: Promising Results in Treating Relapsed/Refractory Follicular Lymphoma: Findings from Phase II Study ELM-2 Tae Min Kim MD By Tae Min Kim, MD, PhD Our clinical trial is using the CD20xCD3 bispecific antibody and a monoclonal antibody targeting the follicular lymphoma cells in the second line failure setting. Our clinical trial shows the very highest complete response rate so far with doable and deep responses in the refractory and relapsed follicular lymphoma patient. What is the standard of care in this disease state, and why did you choose to pursue this clinical trial? Yes, approximately, and regarding the relapse…
REGN5458: A Trial for Relapsed/Refractory Multiple Myeloma a BCMAxCD3 Bispecific Antibody Naresh Bumma MD By Naresh Bumma, MD – Ohio State University – The James The current stage for multiple myeloma treatment has changed very drastically in the last few years, with drugs such as anti-CD38 antibodies (bispecific antibodies), IMiDs, and chromosome inhibitors being used earlier and earlier. And that has led to a need for novel therapies that use novel, newer agents to treat multiple myeloma. B-cell maturation agent, or BCMA, has come up as one of these targets on the plasma cell that has been utilized to treat…
Zanubrutinib Outperforms Ibrutinib in Treating Relapsed/Refractory CLL/SLL Mehrdad Mobasher MD By Mehrdad Mobasher, MD, MPH The ALPINE study was a phase 3 clinical trial done in relapsed/refractory CLL and SLL (small lymphocytic leukemia). This is the final analysis of PFS of this study. This study now shows Zanubrutinib (brand name(s) BRUKINSA a tyrosine kinase inhibitor) demonstrates superior progression-free survival. Compared to standard Ibrutinib, in the past we had presented interim analysis of overall response rate, and Zanubrutinib had already shown superiority of overall response rate. Zanubrutinib has other indications that we have FDA approved, globally we have more than in…
Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemcitabine) Versus IV Gemcitabine and nab-paclitaxel for Pancreatic Cancer Treatment By Michael Pishvaian, MD, PhD With positive outcomes, do you see any other tumor types where RenovoGem should be studied and could potentially make an impact? The other thing that’s interesting is that if this study proves positive, ultimately, it really will affirm the idea that delivering local therapy to a tumor can enhance the overall survival for patients even while they’re receiving integrated systemic therapy. And we’ve seen this in other cancer types, with for…
Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemcitabine) Versus IV Gemcitabine and nab-paclitaxel for Pancreatic Cancer Treatment By Micheal Pishvaian, MD, PhD How does this data compare to what you have seen, historically, in patients with locally advanced pancreatic cancer? Locally advanced pancreatic cancer is really a stage of cancer that has only been defined in the last maybe 10 or 15 years. If you look back to the early 2000s, and certainly before then, many of the patients with what we would now define as locally advanced unresectable pancreatic cancer, were lumped…
Renal Cell Carcinoma Trials: Guidelines and Eligibility According to ASCO-FCR: An Overview of RCC Trials Anna Odell by Anna Odell, City of Hope – Friends of Cancer Research So essentially, ASCO, as well as, the Friends of Cancer Research, were concerned that certain characteristics of trials would be underrepresented in studies because of overly restrictive eligibility criteria. So at City of Hope, what we did is we took a handful of phase 1 through 3 trials in patients with urothelial cancer. And we took trials that ranged from June, 2012 to June, 2022, so a 10 year time span. And…
Renal Cell Carcinoma Trials: ASCO-FCR Guidelines for Renal Cell Carcinoma Trial Eligibility Ishann Sehgal by Ishann Sehgal, City of Hope – Friends of Cancer Research So my poster is about Eligibility Criteria Towards Retinal Cell Carcinoma, which is kidney cancer. And our results were that HIV positivity and Hepatitis B and C positivity were most exclusive to patient. And also that brain metastases and concurrent malignancies were very inclusive towards patients. What are questions you received from oncologists about your poster? So some of the questions were, what are next steps after this study and what we found was…
HER2 Low Breast Cancer: What Are the Latest Advancements in Novel Drug Antibody Conjugates for 2023? Yuan Yuan MD By Yuan Yuan, MD, PhD There have been so many exciting things in our field, most recently including antibody drug conjugates specifically Trastuzumab Deruxtecan a monoclonal antibody in the HER2 low disease had largely changed our view of breast cancer. We used to put breast cancer into three bucket of triple-negative, HER2-positive, and ER positive. Now the HER2 low actually removed the old barrier and then put them into HER2 low was non HER2 low, so that’s very exciting. The data…
Novel Therapies for Patients with Genetourinary Malignancies By: Rana R. McKay, MD – Medical Oncologist University of California San Diego During my presentation, I was discussing novel therapies for patients with genetic urinary malignancies. We went through a series of targeted therapies, immunotherapies, radio ligand therapies for patients with. State kidney and bladder cancer. To give a highlight, we talked about Belzutifan and renal cell carcinoma. Belzutifan is a HIF two alpha inhibitor that has shown great promise and is looking to see additional data in the future in urothelial cancer. We talked about the combination of pembrolizumab plus…
Lung Cancer EGFR: What Are The Latest Advanced Treatments in 2023? Insights from Ravi Salgia MD By Ravi Salgia, MD, PhD As I said, I’ve been in practice for a long time and I was on the East Coast and then the Midwest and the West Coast. The lung cancer population is different and we know on the West Coast. There are a lot of non-smokers and we know that there can be a lot of molecular alterations in lung cancer, so molecular alterations such as EGFR can happen, but there are many molecular alterations of EGFR, such as the…
Urothelial Cancer: What’s New in 2023? Targeted and Novel Therapies Nataliya Mar MD By Nataliya Mar, MD Good afternoon, everyone. It’s my pleasure to be the last speaker of the afternoon. So today, I thought, since we had so many wonderful speakers before me who went through so many clinical trials and the data, I thought that this would be a little bit different. And we’re going to zoom out a little bit from the clinical trial world and focus a little bit more on how oncology as a field evolved in the past 20 years, let’s say and…
Insights on Breast Cancer Treatment: Yuan Yuan, MD’s Discussion on Sacituzumab Govitecan and Other Novel Treatments By Yuan Yuan, MD, MPH Today we’re gonna take this chance to review breast cancer immunotherapy and novel drug antibody conjugates. This is my disclosure, so. So let’s, when we talk about breast cancer immunotherapy, we’re gonna start with triple negative breast cancer,no-brainer because triple negative breast cancer is currently the only space we have. FDA-approved immunotherapy now talks about a triple negative breast cancer. You all know that it’s a very challenging disease despite all the improvement we made so far. We’re still…
How effective is mosunetuzumab in treating lymphoma? – Elizabeth Budde, MD 2023 reviews new therapies By Elizabeth Budde, Md, PhD Thank you so much for the invitation. This is actually my first time joining the meeting and it’s been very exciting. I’m learning a lot about medical oncology and all the exciting new drugs. Now, some of the naturally, pretty similarly are also using the in the domain.. How do I get started? Oh, great. Yeah, so I was assigned the task to talk about novel regimens and agents in lymphoma. So it’s a switch from medical oncology, but I…
Lung Cancer Trials: Insights into Latest Clinical Trials in Thoracic Oncology – Expert Analysis from Ravi Salgia, MD By Ravi Salgia, MD, PhD Thank you. After that introduction, I think my time is over, we can take questions now. If I can have my first slide. So for today, it’s a whirlwind of a talk to talk about lung cancer and we’ve certainly come a long way, but I’ll try to emphasize EGFR, KRAS, ALK and immunotherapy for non-small cell lung cancer. Lung cancer, as is a quite devastating illness. I’ve been in practice for over 33 years now and…
Belzutifan and other Novel Therapies in Genitourinary Oncology 2023 By Rana McKay, MD – University of California San Diego We’re gonna start with kidney cancer and go through Belzutifan, Relatlimab, SRF-388 and the others that are listed here. Then we’ll go into. And finally urothelial cancer. This is gonna be a little bit of a whirlwind, splash on each of these drugs where they’re at. And then tie it all up at the end. Renal Cell Carcinoma 2023 Update So we’ll start with kidney cancer and first we’ll talk about Belzutifan. and it’s, I have to say it’s been amazing…
Gastrointestinal Malignancies Research Advancements: Insights from Farshid Dayyani, MD By Farshid Dayyani, MD, PhD Thank you so much for inviting me to this meeting. I was asked to give an overview of research in GI malignancies, and I made 200 slides. Then I realized we have 25 minutes. I practiced this morning. I can’t do it in 18 minutes, so it will be a very concise, here’s my disclosures. What I will try to do is I think I’ll show you very recent data, let’s say the past year or so, where I think the practice might change based on…
Health Inequity in Cancer Research: Examining and Uncovering the Disparities by Hala Borno MD By Hala Borno, MD What also energizes me is that while I was walking down here, I was smiling because I actually got married in this hotel about 10 years ago in the ballroom where the NAFFLE Conference is going on right now. It is just very interesting nostalgia that I was experiencing, but I am delighted to be here and very grateful for the invitation to speak with you. So today I’ll be talking about a topic that’s very near and dear to my heart,…
Leptomeningeal Disease: Phase 1 Trial of BBB-Penetrant HER2 Inhibitor in Metastatic Breast Cancer Nicholas McAndrew MD By Nicholas McAndrew, MD, MSCE DZD1516 is a is a new compound, it’s a new oral tyrosine kinase inhibitor that was designed by the company. When the company initially was developing this drug. They were seeking compounds that were going to be highly HER2 selective and blood-brain barrier penetrant. Because HER2 positive breast cancer is a high rate of CNS metastases, and so it remains 1 of the biggest challenges, although we do now have some compounds out on the market like Tucatinib and…
Polygenic Risk Score: Validation of a Breast Cancer Risk Prediction Model in a Large Prospective Cohort Thomas Slavin, MD By Thomas Slavin, MD When we think about polygenic risk score, it is fairly new. We are doing a lot of the innovation at Myriad. We’ve been doing a lot to restructure the company focused down on women’s health, oncology, mental We’re thinking very differently. We’re trying to be more collaborative, unique access and equity advancements and continue to innovate really heavily in that area. And this is really one of those examples where we saw amazing science going on in…
Endocrine Therapy: 70-Gene MammaPrint Test Predicts Benefit in Early-Stage Breast Cancer Laura Van ’t Veer By Laura Van ‘t Veer, MSC, PhD Breast cancer patients who are diagnosed with breast cancer that is endocrine sensitive. So those tumors that are estrogen receptor positive, their standard of treatment is 5 years of endocrine treatment, Tamoxifen or tyrosine kinase inhibitor. So recent trials have shown that an extension of that 5 years to 10 years benefits patients that which there’s some benefit in survival. But the question has been for some time, who benefits because it’s only a modest benefit and the…
NanoString: Intrinsic Subtypes and 21-Gene Assay Predict Recurrence in Early Stage HER2+ Breast Cancer from Saranya Chumsri MD By Saranya Chumsri, MD Breast cancer is a complex disease with many different subtypes that can impact treatment decisions and patient outcomes. HER2-positive breast cancer is a subtype that is characterized by the overexpression of the HER2 protein, and accounts for approximately 20% of all breast cancer cases. The North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) Trial was a large, randomized clinical trial that evaluated the use of chemotherapy and trastuzumab (Herceptin) in the treatment of HER2-positive breast cancer. The…
Breast Cancer Index: Prospective Evaluation Insights from Kai Treuner PhD By Kai Treuner, PhD So the breast cancer index is a test that’s been developed for the extended endocrine decision making. So in particularly women that are hormone receptor positive that usually get 5 years of endocrine therapy at the 5 year point they have to face the question, is extension of that endocrine therapy beneficial for me or not? So that’s the answer that the BCI provides the breast cancer index we are providing a prognostic answer. So what is the risk of recurrence as well as the prediction…
PACE Trial: Palbociclib, Fulvestrant, and Avelumab in Endocrine Pre-treated Metastatic Breast Cancer Erica Mayer MD By Erica Mayer, MD So a very important standard of care for our patients with metastatic hormone receptor positive HER2-negative breast cancer is using a CDK4/6 inhibitor in combination with endocrine therapy. These are wonderful medicines and they provide great benefit for patients, however, eventually the cancer progresses and a big question has been, when is it time to change therapy? Do you change the, just the endocrine therapy and continue the CDK4/6 inhibitor, or is it time to stop the CDK4/6 inhibitor? So the…
Polygenic Risk Score: Validation of a Breast Cancer Risk Prediction Model in a Large Prospective Cohort Thomas Slavin, MD By Thomas Slavin, MD When we think about polygenic risk score, it is fairly new. We are doing a lot of the innovation at Myriad. We’ve been doing a lot to restructure the company focused down on women’s health, oncology, mental We’re thinking very differently. We’re trying to be more collaborative, unique access and equity advancements and continue to innovate really heavily in that area. And this is really one of those examples where we saw amazing science going on in…
Endocrine Therapy: 70-Gene MammaPrint Test Predicts Benefit in Early-Stage Breast Cancer Laura Van ’t Veer By Laura Van ‘t Veer, MSC, PhD Breast cancer patients who are diagnosed with breast cancer that is endocrine sensitive. So those tumors that are estrogen receptor positive, their standard of treatment is 5 years of endocrine treatment, Tamoxifen or tyrosine kinase inhibitor. So recent trials have shown that an extension of that 5 years to 10 years benefits patients that which there’s some benefit in survival. But the question has been for some time, who benefits because it’s only a modest benefit and the…
NanoString: Intrinsic Subtypes and 21-Gene Assay Predict Recurrence in Early Stage HER2+ Breast Cancer from Saranya Chumsri MD By Saranya Chumsri, MD Breast cancer is a complex disease with many different subtypes that can impact treatment decisions and patient outcomes. HER2-positive breast cancer is a subtype that is characterized by the overexpression of the HER2 protein, and accounts for approximately 20% of all breast cancer cases. The North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) Trial was a large, randomized clinical trial that evaluated the use of chemotherapy and trastuzumab (Herceptin) in the treatment of HER2-positive breast cancer. The…
Breast Cancer Index: Prospective Evaluation Insights from Kai Treuner PhD By Kai Treuner, PhD So the breast cancer index is a test that’s been developed for the extended endocrine decision making. So in particularly women that are hormone receptor positive that usually get 5 years of endocrine therapy at the 5 year point they have to face the question, is extension of that endocrine therapy beneficial for me or not? So that’s the answer that the BCI provides the breast cancer index we are providing a prognostic answer. So what is the risk of recurrence as well as the prediction…
PACE Trial: Palbociclib, Fulvestrant, and Avelumab in Endocrine Pre-treated Metastatic Breast Cancer Erica Mayer MD By Erica Mayer, MD So a very important standard of care for our patients with metastatic hormone receptor positive HER2-negative breast cancer is using a CDK4/6 inhibitor in combination with endocrine therapy. These are wonderful medicines and they provide great benefit for patients, however, eventually the cancer progresses and a big question has been, when is it time to change therapy? Do you change the, just the endocrine therapy and continue the CDK4/6 inhibitor, or is it time to stop the CDK4/6 inhibitor? So the…
Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemcitabine) Versus IV Gemcitabine and nab-paclitaxel for Pancreatic Cancer Treatment By Michael Pishvaian, MD, PhD Locally advanced pancreatic cancer has its own challenges because we’re really focused on trying to treat the tumor where it lies within the pancreas, while also treating the systemic micro metastatic disease that almost certainly is there. It’s also not usually a situation where we’re trying to get the patient to the point of operability. Unfortunately, we know that at least 85% of patients with locally advanced, unresectable pancreatic cancer, as…
Antibody-Drug Conjugate Advancements for Breast Cancer Treatment: Updates from SABCS 2022 by Leif Ellisen MD By Leif Ellisen, MD So antibody drug conjugates, or as I’ll refer to them, ADCs are a really important new class of drugs. They’re very complicated structure in that they have three distinct components. One is an antibody that binds to a target on the surface of the tumor cell. That antibody is linked or conjugated to what we call a “cytotoxic payload,” typically a chemotherapy like drug, and when it’s linked to the antibody, that chemotherapy drug is carried into the cell. When the…
Invasive Lobular Breast Cancer: Steffi Oesterreich Shares Insightful Learning Sessions Exploring ILBC at SABCS 2022 By Steffi Oesterreich, PhD So, I was very excited about increasing attention to special subtypes of breast cancer. There was actually a unique session, an educational session called Challenging Types of Breast Cancer: Lobular/Pleomorphic, and I was very excited because invasive lobular breast cancer, which affects approximately 10 to 15% of all breast cancers, received quite a bit of attention there. I think in prior years that didn’t happen so much here at the San Antonio Breast Cancer Symposium (SABCS), so this was really…